Chronic M30 treatment fully restored (-47%/PHF1; -65%/AT8; p<0.05) STZ-induced hyperphosphorylation of tau protein and normalized decreased expression of insulin degrading enzyme (+37%; p<0.05) in hippocampus.
INTRODUCTION
Alzheimer's disease (AD) is a neurodegenerative disorder clinically characterized by a progressive memory decline. Novel and effective therapeutic approach for AD is urgently needed which should be tested pre-clinically in animals models that mimic familial and sporadic AD form (sAD). Widely exploited transgenic animal models of AD (Lithner et al. 2011 ) represent the familial form of AD and do not mimic the sAD condition (Balducci and Forloni 2011) . Animal model which develops insulin resistant brain state and glucose hypometabolism following the intracerebroventricular application of a betacytotoxic drug streptozotocin in small rodents and cynomolgus monkey (STZ-icv model), (Agrawal et al. 2011; Grünblatt et al. 2007; Lannert and Hoyer 1998; Lee et al. 2014; Lester-Coll et al. 2006; Plaschke and Hoyer 1993; Salkovic-Petrisic et al. 2006) , shares similarities with the human sAD condition (Lannert and Hoyer 1998) since insulin resistant brain state was found postmortem in sAD patients (Correia et al. 2011; de la Monte and Wands 2005; Frölich et al. 1998 ). Additionally, STZ-icv model demonstrates also cognitive deficits (Mayer et al. 1990; Lannert and Hoyer 1998) and decrement in cerebral cholinergic transmission (Blokland and Jolles 1993; Hellweg et al. 1992) , as well as other features of chronic neurodegeneration like oxidative stress and neuroinflammation (Saxena et al. 2011; Sharma and Gupta 2001) and in particular tau protein hyperphosphorylation (Grünblatt et al. 2007; Deng et al. 2009; Liu et al. 2014; Peng et al. 2013) , pathological Aβ accumulation (Shingo et al. 2013 ) and cerebral amyloid angiopathy (Salkovic-Petrisic et al. 2006 , 2011 .
Considering the involvement of iron accumulation in AD pathophysiology (Grünblatt et al. 2010; Honda et al. 2004) , metal chelation has become one of the therapeutic strategies for the treatment of AD (Budimir 2011) . Deferoxamine (DFO), the natural prototype iron chelator/radical scavenger slowed the clinical progression of AD dementia (Crapper et al. 1991 ) and inhibited amyloidogenic processing of amyloid precursor protein (APP) and reversed iron-induced memory deficits and tau phosphorylation in mice model of AD (Guo et al. 2013a,b) . Clioquinol and PBT2, 8-hydroxyquinoline bidentate ligands, attenuated cognitive loss and inhibited Aβ accumulation in AD transgenic mice (Cherny et al. 2001; Adlard et al. 2011 ).
Novel anti-AD therapeutic strategies focus on drugs which target multiple pathology aspects of the disease (Van der Schyf et al. 2006; Youdim and Buccafusco 2005) . M30 ([5-(N-methyl-N-propargyaminomethyl)-8-hydroxyquinoline] ) and HLA20 (5-{4-propargylpiperazin-1-ylmethyl}-8-hydroxyquinoline) are multi-target compounds with iron chelating potency, radical scavenging activity and features of inhibition of iron-induced lipid peroxidation (Zheng et al. 2005) . Neuroprotective activity of M30 was found in vitro and in some animal models of neurodegenerative disorders (Zheng et al. 2005; Weinreb et al. 2011 ).
Systemic treatment of transgenic (APP/presenilin 1) mice with M30 for 9 months, attenuated cognitive impairments, reduced cerebral iron accumulation, modulated glucose metabolism and reduced APP expression, Aβ accumulation and tau phosphorylation (Kupershmidt et al. 2012; Mechlovich et al. 2014a ).
Using the non-transgenic STZ-icv rat model of sAD, we herein aimed to assess the effectiveness of M30 and HLA20 in improving the cognitive deficits and underlying neurochemical alterations.
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MATERIALS AND METHODS
Materials
Streptozotocin was purchased from Sigma-Aldrich (Munich, Germany). 5-{N-methyl-N- 
Animals
Three to four-month old male Wistar rats weighing 280-330 g (Department of Pharmacology, University of Zagreb School of Medicine) were used throughout the studies. The rats were kept 2-3 per cage in a room with a 12 h light/12 h dark cycle (lights on 07:00 -19:00 h), and the room temperature and humidity set in the range of 21-25°C and 40-70% respectively.
Standardized food pellets and water ad libitum were provided to all animals. Animal care and experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals (8th ed. 2011) and the protocol was approved by the institutional Ethical
Committee. Animals were euthanized after cognitive testing at the end of experiments in deep anaesthesia (thiopental 50 mg/kg/6 mg/kg diazepam intraperitoneally) followed by decapitation. All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny et al. 2010 ).
STZ-icv rat model
Rats were given general anaesthesia (chloral hydrate 300 mg/kg, ip), followed by injection of streptozotocin 1 mg /kg (single dose) or 3 mg/kg (split in two doses on day 1 and 3) administered bilaterally into the left and right lateral ventricle as previously described (Grünblatt et al. 2007; Salkovic-Petrisic et al. 2006 , 2011 . Drug concentration and solution volume were adjusted according to the animal body weight, and a volume of 4 μL per 300 g body weight was administered (2 μL/ventricle). Control animals received bilaterally an equal volume of vehicle (0.05 M citrate buffer pH 4.5) into the lateral ventricles. Appropriate care was taken during anaesthesia and recovering period to reduce the pain and discomfort as much as possible. STZ-icv treated animals were randomly allocated to receive iron-chelator or saline.
Iron-chelator treatments
HLA20. Neuropreventive paradigm was tested by pre-treatment with saline, or HLA20 (5 mg/kg/day), administered by oral catheter (adjusted for volume of 1 mL/300 g body weight)
for 5 days (9:00 to 10:00 h). On the 5 th day, a single STZ-icv (1 mg/kg) or vehicle-icv injection was given after the last HLA20 oral dose. Animals were sacrificed 1 month following the STZ-or vehicle-icv treatment. In additional experiment, rats were pre-treated for 5 days with HLA20 (10 mg/kg/day), similarly as in the previous experiment, but were sacrificed 3 months following the STZ-icv injection.
M30. Neuropreventive paradigm was tested by pre-treatment with saline or M30 (10 mg/kg/day), administered by oral catheter (1 mL/300 g body weight) for 5 days (9:00 to 10:00 h). On the 5 th day, a single STZ-icv (1 mg/kg) or vehicle-icv injection were given after the last M30 dose and animals were sacrificed 1 month later.
M30
. Neurorescue paradigm activity was tested by post-treatment with M30 administered in two doses (2 and 10 mg/kg/day, on Monday, Wednesday and Friday during each treatment week) by oral catheter (1 mL/300g body weight), for 11 weeks (9:00 to 10:00 h), starting from the 8 th day following the first (out of two) STZ-icv injection (3 mg/kg). Control STZ-icv rats were orally treated by saline in a similar way. All animals were sacrificed 3 months following the first STZ-icv injection. Additional short-term experiment of a similar design was performed to test the activity of high (10 mg/kg/day) M30 dose on neurochemistry parameters (control, STZ and STZ+M30 group). Oral M30 treatment was initiated from the 8 th day following the first (out of two) STZ-icv injection (3 mg/kg) and animals were euthanized a week later, after being administered with 3 M30 doses only (on Monday, Wednesday and Friday).
Cognitive performance assessment
Cognitive performance assessment was done by Morris Water Maze Swimming test (MWM, 8:00-13:00 h), which tests spatial memory, and Passive Avoidance (PA, 8:00-9:00 h) test, which tests fear-motivated avoiding memory. In the M30 neuropreventive paradigm MWM was performed once before the sacrifice, while in the M30 neurorescue paradigm, MWM was performed repeatedly after 2 weeks and 1, 2 and 3 months post-STZ-icv injection and PA was performed only once before the sacrifice. In the HLA20 -5 mg/kg neuropreventive paradigm, MWM and PA were performed once before the sacrifice, while in another HLA20 -10 mg/kg neuropreventive paradigm, MWM was performed repeatedly after 2 weeks and 1, 2 and 3 months post-STZ-icv injection. No cognitive testing was done in a short-term experiment in neurorsecue paradigm.
MWM Test
On the first day of adaption to the environment, rats were subjected to 1 min of freely swimming in a pool (150x60 cm, 50 cm deep), with water temperature set at 25±1 o C, and on the second day rats were allowed to freely swim in the pool divided in four compartments (I-IV). The acquisition or training phase was performed afterwards from day 1 to day 4, during which the rats were thought to escape from water by finding a hidden rigid platform submerged about 2 cm below the water surface in compartment IV. Stay on the platform was allowed for 15 s. One training trial consisted of three starts, each from a different compartments (I -III), separated by a 1-min rest period. Three consecutive trials were performed per day, separated by a 30-min rest period. Escape latency (time needed to find the platform) and number of errors (entries into the compartments without a platform) were recorded as parameters of the reference memory (memory acquisition). After the third training trial on day 4, the probe trial was performed (starts from compartments I-III) with a platform being removed from the pool, and the time spent within the compartment IV (from which the platform was removed) and the number of errors were recorded as parameters of the working memory (memory retention). The cut off time was 1 min.
PA test
The rats were placed in a light compartment of a shuttle box (Ugo Basile, Comerio, Italy) on the 1 st test day for acclimatization. The light compartment has been isolated from the dark compartment by a guillotine door which is closed automatically after entry of the rat into the dark compartment. On the 2 nd test day, during the acquisition trial, animals were placed again into the light compartment and after entry into the dark compartment, received a low-intensity electric foot shock (0.5 mA; 2 s) delivered through the grid metal floor in the dark compartment. During the retention trial, animals were again placed in the light compartment and the post-shock latency time spent within the light compartment before entering the dark one was recorded.
Western blot analysis
Tissue preparation.
Hippocampal (1 animal = 1 sample) tissue samples from one half of the rat brain were homogenized with 3 volumes of lysis buffer containing 10 mM HEPES, 1 mM EDTA, 100 mM KCl, and 1% Triton X-100, pH 7.5, and protease inhibitors coctail (1:100), and the homogenates were centrifuged at 12000 rpm for 10 min at 4°C and the supernatant were frozen and stored at -80°C. Protein concentration was measured by Lowry protein assay.
Immunoblotting.
Equal amounts of total protein (35 μg per sample) were separated by SDS-PAGE using 9%
polyacrylamide gels and transferred to nitrocellulose membranes. The nitrocellulose membranes were blocked by incubation in 5% non-fat milk added to low salt washing buffer (LSWB) containing 10 mM Tris and 150 mM NaCl, pH 7.5, and 0.5% Tween 20 for one hour at room temperature. Blocked blots were incubated overnight at 4°C with anti-IDE (1:2000),
anti-AT8 (1:500), anti-total tau (1:500) or overnight at RT with primary anti-PHF1 (1:500).
Following the incubation, the membranes were washed three times with LSWB and incubated for 60 min at room temperature with appropriate secondary antibody solution (anti-mouse or anti-rabbit IgG, 1:5000). The specificity of the signal was checked on the control membranes that were not incubated with the primary antibody. After washing three times in LSWB, the membranes were immunostained using chemiluminiscence Western blotting detection reagents, signal captured and visualised with the MicroChemi 2.0 CCD camera system (DNR Bio-Imaging Systems) and after that washed three times in LSWB and incubated with loading control, anti-GAPDH (1:2000) or anti-βactin (1:5000) antibody followed by the same procedure already mentioned above.
Statistics
For all experiments based on comparisons of independent groups (N=7-10 rats per group), data were expressed as mean±SEM and analysed using non-parametric ANOVA (KruskalWallis) followed by Mann-Whitney U-test, or by parametric ANOVA followed by Tukey 
RESULTS
Effect of M30 on STZ-icv-induced memory impairment Neuroprevention
In comparison to control animals, STZ-icv treatment induced memory impairment in rats, as detected in the probe MWM trials, 1 month after the treatment (Fig. 1A) . STZ-icv treated rats had a poor memory on the location of the compartment with a platform and thus had more entries into the incorrect compartments (increased number of mistakes, p<0.05), spending less time swimming within the targeted compartment from which the platform had been previously removed, p<0.05 (Fig. 1B) . Five-day oral pre-treatment with M30 (10 mg/kg/day) significantly prevented development of spatial memory impairment in STZ-icv treated rats, which was manifested by reducing the number of mistakes ( 
Neurorescue
The therapeutic potential of M30 on spatial learning and memory impairment, as well as on fear motivated escape memory deficits in STZ-icv rat model of sAD, has been also tested in a neurorescue experimental design by MWM and PA test, respectively.
MWM test
Learning and memory performance in training trails over time. A total of 4/33 animals died during the course of the experiment ( (Fig. 2B) ; b) M30 dose-dependently antagonized the STZ-icv-effect; differences vs. control were still significant but lower, and the number of errors was lower, as compared to STZ-icvtreated rats: RR=0.68, p<0.001 and RR=0.25, p<0.001, for M30 (2 mg/kg and 10 mg/kg), respectively (Fig. 2B) . The effects of the treatments on escape latency time followed the same pattern (Fig. 2C ). As shown in Fig. 2D , when escape latency was analysed with adjustment for the number of errors (as a time-varying covariate), no major effect was observed, indicating that the main effect was on number of entries into incorrect compartments (number of errors) resulting in longer time needed to escape from water onto the platform. Therefore, specific statistical evaluation of learning capacity over time and long-term acquisition/retention of memory focused on the number of errors. The main points are summarized in Table 1 . Controls retained constant relative learning capacity throughout the experiment. STZ-icv-treated rats had significantly reduced learning capacity (vs. controls) in the 1 st (p<0.001) and 2 nd (p=0.029) cycles, but with repeated trainings, the capacity increased and was, in relative terms, close to that in controls, yet at a higher absolute level of the number of errors. M30 (10 mg/kg) antagonized STZ-icv-induced impairment. Day 1 values decreased over time (cycles) in all groups (development of memory), but markedly more in controls than in STZ-icv-treated rats (p<0.001). The decrease with M30 (2 mg/kg) was similar to that of STZ-icv alone (p=0.480), but less than in controls (p=0.003), while the decrease with M30 (10 mg/kg) was similar to that in control animals (p=0.122) and significantly more pronounced than in STZ-icv-treated rats (p=0.010) (Fig. 2E) . In summary, the data illustrate (Fig. 3) . Time-course data, recorded in the probe trials within the STZ-icv group support the above-mentioned limited capacity of retaining the spatial memory; STZ-icv rats have retained limited memory of the pathway to the platform making less incorrect entries as the repetition of MWM trials increased in the course of 2 and 3 months after STZ-icv treatment (p<0.05) (Fig. 3A) . In the STZ-icv-treated group, the tendency for limited improvement in the course of time is seen in the time spent in targeted compartment, which however, has not reached the significant level (Fig. 3B) . Treatment with M30, initiated 8 days after STZ-icv, ameliorated STZ-induced memory deficits, affecting primarily the number of mistakes in the MWM probe trial (Fig. 3A) . The number of mistakes in M30 (10 mg/kg)-treated STZ-icv group was significantly reduced (p<0.05) in comparison to STZ-icv treated rats, at 2 weeks and 2 and 3 months following the STZ-icv administration (Fig. 3.3A) . The effect was clearly dosedependent, as the STZ-icv group treated with M30 (10 mg/kg) demonstrated significantly reduced number of mistakes, compared to that observed in the group treated with the lower, 2 mg/kg M30 dose, which was ineffective in this respect (Fig. 3A) . However, both M30 doses were almost ineffective in increasing the time within the targeted compartment in STZ-icv treated rats, with the exception of the 2-month time-point, when a significant increase was achieved with the high M30 dose, in comparison to the STZ-icv treatment alone (Fig. 3B) .
Failure of the high M30 dose to increase the time spent within the targeted compartment at 3-month time point might be related to the number of animals in this group at that time point.
Similar to the control group, the STZ-icv group treated with the higher M30 dose demonstrated preserved capability to retain memory over time, as shown by increased time spent in targeted compartment after 1 and 2 months in comparison to 2 weeks after STZ-icv treatment (p<0.05) (Fig. 3B ). This beneficial effect was missing in STZ-icv group treated with a low M30 dose (Fig. 3B ).
PA test
Eleven-week long treatment with M30 (10 mg/kg), initiated 8 days following the STZ-icv injection, successfully restored STZ-icv induced impairment in fear-motivated escape memory in PA test (Fig. 4) , while M30 (2 mg/kg) was ineffective in this respect, as latency time remained similar to STZ-icv treatment alone (Fig. 4) .
Neuropreventive effect of HLA20 on STZ-icv-induced memory impairment
Further experiments have been performed in order to examine the effect of HLA20, a chemically different multifunctional compound, which shares the iron-chelating activity with M30, on STZ-icv-induced cognitive deficits.
Five-day oral pre-treatment with HLA20 (5 mg/kg) significantly decreased the number of mistakes in the MWM probe trial (Fig. 5A ) and increased the time spent within the targeted compartment (Fig 5B) , in comparison to the STZ-icv treatment alone (p<0.05). HLA20 (5 mg/kg) also prevented STZ-icv-induced impairment in fear-motivated escape memory in the PA test, measured 1 month after STZ-icv treatment and increased latency time (p<0.05), compared to the STZ-icv treatment alone (Fig. 5C ). Oral pre-treatment with a higher, HLA20
dose (10 mg/kg) exerted a neuropreventive effect in STZ-icv-treated rats in the MWM probe trial already after 2 weeks, seen both as less entries into the incorrect compartments ( Fig. 6A) (p<0.05) and longer time (Fig. 6B ) (p<0.05) within the targeted compartment, in comparison to the STZ-icv treated rats. The latter effect of HLA20 was persistent up to 3 months after STZ-icv treatment, while the significance of the former vanished in the course of time (Fig.   6A ). HLA20 to buffer-icv-treated rats had no effects on cognitive performance, compared to control rats, with the exception of the beneficial effect (reduction of mistake number) seen of 2 weeks (Fig. 6A ).
Beneficial effect of M30 on STZ-induced decrement in IDE level and on tau hyperphosphorylation
Possible molecular mechanisms underlying M30 beneficial effects on cognitive performance in the neurorescue paradigm were explored at the level of IDE and tau protein (AT8/PHF1), two parameters which build up the pathophysiological core of AD.
While IDE expression in hippocampus was found unaffected 2 weeks after STZ-icv treatment, it was significantly decreased (-21%, p<0.05) after 3 months (Fig. 7A, F) . Longterm treatment with both low and high M30 dose in neurorescue paradigm significantly increased IDE expression in comparison to the STZ-icv treatment alone (+19% and +37%, p<0.05) and normalized it to the levels of controls (Fig. 7A, F) .
Compared to controls, significant increase in PHF1 phospho tau expression and in PHF1 phospho/total tau ratio was detected 2 weeks (+328% and +461%, p<0.05) and 3 months following STZ-icv administration (+120% and +215%, p<0.05) (Fig. 7B, C, G, H) . Long-term treatment with high M30 dose (10 mg/kg) in the neurorescue paradigm completely normalized STZ-induced increment in both PHF1 expression (p<0.05) and PHF1/total tau ratio (p<0.05) to the control levels, measured 3 months after STZ-icv administration (Fig. 7G,   H ). Low M30 dose was ineffective in this respect (Fig. 7G, H) . This beneficial effect of high dose begun to be manifested already after a week of M30 treatment (i.e. 2 weeks after STZicv treatment) when significantly reduced STZ-induced increment in PHF1/total tau protein ratio (-42%, p<0.05) was found in comparison to STZ treatment alone (Fig. 7C ). Long-term treatment with high M30 dose (10 mg/kg) significantly decreased AT8 phospho tau expression in STZ-icv treated rats (-34% and -60%, p<0.05 vs control and STZ), although at that time point, a tendency of STZ-induced increment in AT8 expression did not reach the level of significance (Fig. 7D , E, I, J).
DISCUSSION
Numerous clinical AD trials failed to confirm the effectiveness of drugs tested so far (Mangialasche et al. 2010 ) which, among other reasons, could be due to focusing on the inappropriate mechanism of drug action based on the incorrect understanding of the primary pathophysiological core of the disease. Mechanisms of action, other than those affecting primarily Aβ homeostasis or tau phosphorylation and assembly, which have all targeted a single pathological process (Salomone et al. 2012) , have been rather neglected. Additionally, a growing body of evidence indicates that there might be different sAD endophenotypes (e.g.
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apolipoprotein E positive and negative individuals) (Borroni et al. 2006) , suggesting that choosing the animal model, which mimics a specific endophenotype (e.g. "brain insulin resistance" endophenotype) might contribute to a more successful translation of the results to the corresponding endophenotype of sAD population (Zahs et al. 2010) .
Considering the diverse etiological nature of AD forms, novel therapeutic strategies should be focused on the implementation of drugs directed to various neuronal targets to address the multiple pathology aspects of the disease (Van der Schyf et al. 2006; Youdim and Buccafusco 2005) . The homeostasis of brain iron is thought to be necessary for normal brain function, especially in learning and memory (Youdim et al. 1989) . iron-chelating agent (HLA20) and also with the iron-chelator VK-28 (data not shown), ironchelation seems to be crucial for the cognitive improvement effect of M30 in this model.
The exact mechanism by which STZ-icv treatment impairs cognitive functions still needs to be elucidated, but factors like direct neurotoxicity, brain glucose/energy and cholinergic deficits, oxidative stress and insulin resistant brain state, may all form the biological basis for the marked reduction in learning and memory capacities found in this model. STZ generates intracellular free radicals, nitric oxide and hydrogen peroxide (H 2 O 2 ), and is selectively toxic for insulin producing/secreting cells (Szkudelski 2001) . Regarding the antioxidant properties of M30, recent studies demonstrated that the drug attenuated H 2 O 2 -induced mitochondrial membrane potential loss and displayed significant cytoprotective activity against cytotoxicity induced by oxidative stress in insulin producing beta-cells (Mechlovich et al. 2010 ).
Therefore, neuroprevention in the M30 pre-treatment studies could be related to the antioxidative activity of M30 against acute STZ-icv-induced oxidative stress. Indeed, our preliminary data showed that M30 pretreatment prevented STZ-icv-induced decrement in hippocampal catalase activity (Sofic et al. 2014) . However, therapeutic effects of M30 in the neurorescue design could be related, in addition to the antioxidant activity, also to the iron- Recent reports have indicated that M30 exerted various beneficial neuroprotective regulatory effects that might be attributed to the multimodal design paradigm of the drug; including up regulation of insulin/insulin receptor/phospho-glycogen synthase kinase β levels, activation of hypoxia-inducible factor-1 pathway, and antioxidation (Mechlovich et al. 2014a,b) . It was reported that M30 significantly reduced iron accumulation in the cortex of aged mice 22 (Kupershmidt et al. 2012) . Our results have confirmed the previous finding in transgenic mice AD model (Kupershmidt et al. 2012 ) that the mechanism of beneficial M30-induced cognitive effects might be related to normalization of tau protein hyperphosphorylation in the hippocampus of the non-Tg rat sAD model. This is probably an indirect effect of M30 shown to affect kinases directly involved in regulation of homeostasis of tau protein phosphorylation (Kupershmidt et al. 2012 ). However, we proposed here for the first time an additional mechanism of action and a new possible target for M30 by demonstrating that long-term M30 oral treatment normalizes reduced hippocampal IDE levels. IDE is a metalloprotease responsible for degradation of both insulin and Aβ, and reduced IDE levels in sAD leading to decreased Aβ degradation significantly contribute to the disease pathophysiology. Literature data indicate that iron-induced oxidative stress inactivates IDE (Shinall et al. 2005 ) which might provide an explanation why iron-chelators like M30 could have beneficial effect at the level of IDE, as detected in our experiments for the first time. Decreased IDE protein and gene expression has been found in STZ-icv rat model also by others (Yang et al. 2014 ), but our recent 9-month follow up data on staging of cognitive, neuropathological and neurochemical changes in STZ-icv rat model has shown that the order of pathology appearance after STZ-icv treatment is: tau protein/2 weeks, IDE/1 month, and amyloid β/3 months (Osmanovic Knezovic et al. 2015) , which supports the results presented here.
Control of iron homeostasis in the brain, as achieved by iron-chelating agents like M30, might be also important considering the fact that Aß-upregulation is inducible by two irondependent pathways:
(1) iron induces ROS generation, which, via stimulation of the expression of tissue inhibitor of metalloproteinase-2 (TIMP2), blocks α-secretase and thus provokes β-/γ-secretase induced 23 Aß production. In addition, increased ROS species shift cytoplasmatic aconitase to iron regulatory protein 1 (IRP-1), which stimulates cells to enhance iron uptake due to the wrong IRP-1 induced message of an existing iron deficiency.
(2) iron accumulation down-regulates a proconvertase furin, thus impairing the processing of ADAM 10 and TACE, two metalloproteases that show α-secretase activity and are involved in sAPP production (Silvestri and Camaschella 2008) . Moreover, the proprotein convertase furin promotors reveal the presence of putative binding sites for hypoxia-inducible factor-1 (HIF-1), a transcription complex that plays a pivotal role in cellular adaptation to hypoxia (Mc Mahon et al. 2005 ) and thus offers another link to iron induced pathology (Crichton et al. 2011) . 
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